<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="article-commentary" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">50148</article-id><article-id pub-id-type="doi">10.7554/eLife.50148</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Insight</subject></subj-group><subj-group subj-group-type="heading"><subject>Genetics and Genomics</subject></subj-group><subj-group subj-group-type="heading"><subject>Microbiology and Infectious Disease</subject></subj-group><subj-group subj-group-type="sub-display-channel"><subject>Host-Pathogen Interactions</subject></subj-group></article-categories><title-group><article-title>What makes the hepatitis C virus evolve?</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-125142"><name><surname>O'Brien</surname><given-names>Thomas R</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0003-6065</contrib-id><email>obrient@exchange.nih.gov</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/><bio><p><bold>Thomas R O'Brien</bold> is in the Infections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, United States</p></bio></contrib><contrib contrib-type="author" id="author-102610"><name><surname>Hartmann</surname><given-names>Rune</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1159-066X</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf2"/><bio><p><bold>Rune Hartmann</bold> is in the Department of Molecular Biology at the University of Aarhus, Aarhus, Denmark</p></bio></contrib><contrib contrib-type="author" id="author-125431"><name><surname>Prokunina-Olsson</surname><given-names>Ludmila</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-9622-2091</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf3"/><bio><p><bold>Ludmila Prokunina-Olsson</bold> is in the Laboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, United States</p></bio></contrib><aff id="aff1"><label>1</label><institution content-type="dept">Infections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics</institution><institution>National Cancer Institute, National Institutes of Health</institution><addr-line><named-content content-type="city">Bethesda</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution content-type="dept">Department of Molecular Biology</institution><institution>University of Aarhus</institution><addr-line><named-content content-type="city">Aarhus</named-content></addr-line><country>Denmark</country></aff><aff id="aff3"><label>3</label><institution content-type="dept">Laboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics</institution><institution>National Cancer Institute, National Institutes of Health</institution><addr-line><named-content content-type="city">Bethesda</named-content></addr-line><country>United States</country></aff></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>03</day><month>09</month><year>2019</year></pub-date><pub-date pub-type="collection"><year>2019</year></pub-date><volume>8</volume><elocation-id>e50148</elocation-id><history><date date-type="received" iso-8601-date="2019-08-21"><day>21</day><month>08</month><year>2019</year></date><date date-type="accepted" iso-8601-date="2019-08-21"><day>21</day><month>08</month><year>2019</year></date></history><permissions><ali:free_to_read/><license xlink:href="http://creativecommons.org/publicdomain/zero/1.0/"><ali:license_ref>http://creativecommons.org/publicdomain/zero/1.0/</ali:license_ref><license-p>This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">Creative Commons CC0 public domain dedication</ext-link>.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-50148-v1.pdf"/><related-article ext-link-type="doi" id="ra1" related-article-type="commentary-article" xlink:href="10.7554/eLife.42542"/><related-article ext-link-type="doi" id="ra2" related-article-type="commentary-article" xlink:href="10.7554/eLife.42463"/><abstract><p>Polymorphisms in the <italic>IFNL4</italic> gene that affect both the presence and the form of the coded protein are associated with changes in the hepatitis C virus.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>Hepatitis C</kwd><kwd>host-pathogen interactions</kwd><kwd>interferon-lambda 4</kwd><kwd>innate immunity</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Virus</kwd></kwd-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Polymorphisms in the <italic>IFNL4</italic> gene that affect both the form and the activity of the coded protein are associated with changes in the hepatitis C virus.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><boxed-text><p><bold>Related research article</bold> Chaturvedi N, Svarovskaia ES, Mo H, Osinusi AO. 2019. Adaptation of hepatitis C virus to interferon lambda polymorphism across multiple viral genotypes. <italic>eLife</italic> <bold>8</bold>:e42542. doi: <ext-link ext-link-type="uri" xlink:href="http://doi.org/10.7554/eLife.42542">10.7554/eLife.42542</ext-link></p><p><bold>Related research article</bold> Ansari MA, Aranday-Cortes E, Ip CLC, da Silva Filipe A, Hin LS, Bamford CGG, Bonsall D, Trebes A, Piazza P, Sreenu V, Cowton VM, STOP-HCV Consortium, Hudson E, Bowden R, Patel AH, Foster GR, Irving WL, Agarwal K, Thomson EC, Simmonds P, Klenerman P, Holmes C, Barnes E, Spencer CCA, McLauchlan J, Pedergnana V. 2019. Interferon lambda 4 impacts the genetic diversity of hepatitis C virus. <italic>eLife</italic> <bold>8</bold>:e42463. doi: <ext-link ext-link-type="uri" xlink:href="http://doi.org/10.7554/eLife.42463">10.7554/eLife.42463</ext-link></p></boxed-text><p>When cells are infected with a virus they release proteins known as interferons to fight off the infection. In 2003, a group of proteins called interferon lambda, or IFN-λ for short, were found to activate anti-viral signaling pathways used by other interferons (<xref ref-type="bibr" rid="bib7">Kotenko et al., 2003</xref>; <xref ref-type="bibr" rid="bib10">Sheppard et al., 2003</xref>). It was initially thought that members of the IFN-λ family were simply redundant to well-known interferons. However, a growing body of evidence indicates IFN-λ proteins provide unique ‘first-line’ protection against a wide range of common viruses that can infect the respiratory and gastrointestinal tracts, as well as the brain (<xref ref-type="bibr" rid="bib12">Ye et al., 2019</xref>).</p><p>IFN-λ4 is the most recently discovered member of the IFN-λ family. Production of IFN-λ4 in humans depends on which variant of the <italic>IFNL4</italic> gene a person carries. Individuals with the <italic>IFNL4</italic>-ΔG variant can synthesize the full protein, while those with the <italic>IFNL4</italic>-TT variant produce a truncated protein that is not functional (<xref ref-type="bibr" rid="bib9">Prokunina-Olsson et al., 2013</xref>). Another polymorphism called <italic>IFNL4</italic> P70S produces variants of the full protein with different biological activity: if the amino acid in position 70 is a proline, the protein is fully active, but if it is a serine the protein has reduced biological activity (<xref ref-type="bibr" rid="bib11">Terczyńska-Dyla et al., 2014</xref>). These <italic>IFNL4</italic> genetic variants affect clearance of the hepatitis C virus, and have been associated with the risk of other conditions. These conditions include a rare form of ovarian cancer, more aggressive prostate cancer and liver inflammation and scarring caused by the hepatitis B and C viruses or non-alcoholic fatty liver disease (<xref ref-type="bibr" rid="bib4">Eslam et al., 2015</xref>; <xref ref-type="bibr" rid="bib5">Kelemen et al., 2015</xref>; <xref ref-type="bibr" rid="bib8">Minas et al., 2018</xref>).</p><p>Worldwide, an estimated 71 million people are infected with hepatitis C virus. There are various genotypes and subtypes of HCV and, like other RNA viruses, HCV frequently mutates and can undergo selection for different viral variants. This genetic variability is clinically significant, as some changes in the HCV genome may impair the effectiveness of certain treatments. Paradoxically, although interferons are usually antiviral proteins, patients with the most biologically active form of IFN-λ4 are least likely to clear HCV. On the other hand, patients with the <italic>IFNL4</italic>-TT allele that do not produce active IFN-λ4 have the highest rates of spontaneous clearance and response to treatment (<xref ref-type="bibr" rid="bib9">Prokunina-Olsson et al., 2013</xref>; <xref ref-type="bibr" rid="bib11">Terczyńska-Dyla et al., 2014</xref>).</p><p>Now, in eLife, two collaborations report on the effect of <italic>IFNL4</italic> genotype on the HCV viral genome. Previously, in 2017, Azim Ansari, Vincent Pedergnana and colleagues at the University of Oxford and other institutions reported the results of a genome-to-genome analysis which revealed that the HCV genome evolves in response to the genome of the infected individual (<xref ref-type="bibr" rid="bib1">Ansari et al., 2017</xref>). The analysis showed that HCV viral levels (number of virus particles) and the amino acid sequence of viral proteins depended on whether the patient had the <italic>IFNL4</italic>-TT or the <italic>IFNL4</italic>-ΔG gene variant. In the new eLife papers, researchers based in Oxford, Lausanne and elsewhere examine the association between host <italic>IFNL4</italic> genotype and viral genome variations more broadly.</p><p>In one paper, Ansari, Pedergnana and co-workers – including Elihu Aranday-Cortes and John McLauchlan of the MRC-University of Glasgow Centre for Virus Research – report that the presence of IFN-λ4, and also its biological activity, both affect how HCV evolves (<xref ref-type="bibr" rid="bib2">Ansari et al., 2019</xref>). Ansari et al. analyzed the <italic>IFNL4</italic> genotypes of 485 patients with chronic HCV and the genomes of the virus with which they were infected. To avoid confounding factors, the analysis was restricted to patients of white ancestry infected with HCV genotype 3a. In this new work they show that in addition to the effect of the <italic>IFNL4-</italic>ΔG/TT variant, the <italic>IFNL4</italic> P70S polymorphism, which modulates IFN-λ4 activity, affects the amino acid sequence of HCV.</p><p>In the other eLife paper, Nimisha Chaturvedi, Jacques Fellay (both of the EPFL and the Swiss Institute of Bioinformatics) and colleagues at Gilead Sciences and Goethe University Hospital report the results of a study that included 8729 patients who were infected with a range of HCV genotypes (<xref ref-type="bibr" rid="bib3">Chaturvedi et al., 2019</xref>). This investigation revealed that the polymorphism rs12979860, which serves as a marker for <italic>IFNL4-</italic>ΔG/TT, is associated with amino acid changes in viral proteins across viral genotypes. Different viral polymorphisms were affected in the different viral genotypes. Taken together these new results show IFN-λ4 drives hepatitis C evolution across multiple viral genotypes and that not simply the presence, but also the form of IFN-λ4 contributes to this effect.</p><p>How IFN-λ4 makes HCV evolve remains unknown. Future studies should attempt to elucidate this mechanism, although currently such work is hampered by the transient and cell-specific expression of <italic>IFNL4</italic> in human tissues, and the lack of animal models – neither mice nor rats carry the gene. As the IFN-λ family is known to play a role in a wide range of viral infections, it would be interesting to see whether variants of the <italic>IFNL4</italic> gene affect response to those infections or can drive the evolution of viruses other than HCV. The hypothesis that <italic>IFNL4</italic> genotype affects infections other than HCV is further supported by evidence showing that there has been strong evolutionary selection for <italic>IFNL4</italic>-TT, the variant of the gene that produces an inactive truncated protein (<xref ref-type="bibr" rid="bib6">Key et al., 2014</xref>).</p><sec id="s1"><title>Disclaimer</title><p>The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government.</p></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>This work was supported by the Intramural Research Program of the National Institutes of Health, National Cancer Institute, Division of Cancer Epidemiology and Genetics.</p></ack><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>TRO'B: Co-inventor (with LP-O) on a patent for the IFN-λ4 protein held by the National Cancer Institute.</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf3"><p>LP-O: Co-inventor (with TRO'B) on a patent for the IFN-λ4 protein held by the National Cancer Institute.</p></fn></fn-group><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ansari</surname> <given-names>MA</given-names></name><name><surname>Pedergnana</surname> <given-names>V</given-names></name><name><surname>Ip CL</surname><given-names>C</given-names></name><name><surname>Magri</surname> <given-names>A</given-names></name><name><surname>Von Delft</surname> <given-names>A</given-names></name><name><surname>Bonsall</surname> <given-names>D</given-names></name><name><surname>Chaturvedi</surname> <given-names>N</given-names></name><name><surname>Bartha</surname> <given-names>I</given-names></name><name><surname>Smith</surname> <given-names>D</given-names></name><name><surname>Nicholson</surname> <given-names>G</given-names></name><name><surname>McVean</surname> <given-names>G</given-names></name><name><surname>Trebes</surname> <given-names>A</given-names></name><name><surname>Piazza</surname> <given-names>P</given-names></name><name><surname>Fellay</surname> <given-names>J</given-names></name><name><surname>Cooke</surname> <given-names>G</given-names></name><name><surname>Foster</surname> <given-names>GR</given-names></name><collab>STOP-HCV Consortium</collab><name><surname>Hudson</surname> <given-names>E</given-names></name><name><surname>McLauchlan</surname> <given-names>J</given-names></name><name><surname>Simmonds</surname> <given-names>P</given-names></name><name><surname>Bowden</surname> <given-names>R</given-names></name><name><surname>Klenerman</surname> <given-names>P</given-names></name><name><surname>Barnes</surname> <given-names>E</given-names></name><name><surname>Spencer</surname> <given-names>CCA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Genome-to-genome analysis highlights the effect of the human innate and adaptive immune systems on the hepatitis C virus</article-title><source>Nature Genetics</source><volume>49</volume><fpage>666</fpage><lpage>673</lpage><pub-id pub-id-type="doi">10.1038/ng.3835</pub-id><pub-id pub-id-type="pmid">28394351</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ansari</surname> <given-names>MA</given-names></name><name><surname>Aranday-Cortes</surname> <given-names>E</given-names></name><name><surname>Ip</surname> <given-names>CLC</given-names></name><name><surname>da Silva Filipe</surname> <given-names>A</given-names></name><name><surname>Hin</surname> <given-names>LS</given-names></name><name><surname>Bamford</surname> <given-names>CGG</given-names></name><name><surname>Bonsall</surname> <given-names>D</given-names></name><name><surname>Trebes</surname> <given-names>A</given-names></name><name><surname>Piazza</surname> <given-names>P</given-names></name><name><surname>Sreenu</surname> <given-names>V</given-names></name><name><surname>Cowton</surname> <given-names>VM</given-names></name><collab>STOP-HCV Consortium</collab><name><surname>Hudson</surname> <given-names>E</given-names></name><name><surname>Bowden</surname> <given-names>R</given-names></name><name><surname>Patel</surname> <given-names>AH</given-names></name><name><surname>Foster</surname> <given-names>GR</given-names></name><name><surname>Irving</surname> <given-names>WL</given-names></name><name><surname>Agarwal</surname> <given-names>K</given-names></name><name><surname>Thomson</surname> <given-names>EC</given-names></name><name><surname>Simmonds</surname> <given-names>P</given-names></name><name><surname>Klenerman</surname> <given-names>P</given-names></name><name><surname>Holmes</surname> <given-names>C</given-names></name><name><surname>Barnes</surname> <given-names>E</given-names></name><name><surname>Spencer</surname> <given-names>CCA</given-names></name><name><surname>McLauchlan</surname> <given-names>J</given-names></name><name><surname>Pedergnana</surname> <given-names>V</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Interferon lambda 4 impacts the genetic diversity of hepatitis C virus</article-title><source>eLife</source><volume>8</volume><elocation-id>e42463</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.42463</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaturvedi</surname> <given-names>N</given-names></name><name><surname>Svarovskaia</surname> <given-names>ES</given-names></name><name><surname>Mo</surname> <given-names>H</given-names></name><name><surname>Osinusi</surname> <given-names>AO</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Adaptation of hepatitis C virus to interferon lambda polymorphism across multiple viral genotypes</article-title><source>eLife</source><volume>8</volume><elocation-id>e42542</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.42542</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eslam</surname> <given-names>M</given-names></name><name><surname>Hashem</surname> <given-names>AM</given-names></name><name><surname>Leung</surname> <given-names>R</given-names></name><name><surname>Romero-Gomez</surname> <given-names>M</given-names></name><name><surname>Berg</surname> <given-names>T</given-names></name><name><surname>Dore</surname> <given-names>GJ</given-names></name><name><surname>Chan</surname> <given-names>HL</given-names></name><name><surname>Irving</surname> <given-names>WL</given-names></name><name><surname>Sheridan</surname> <given-names>D</given-names></name><name><surname>Abate</surname> <given-names>ML</given-names></name><name><surname>Adams</surname> <given-names>LA</given-names></name><name><surname>Mangia</surname> <given-names>A</given-names></name><name><surname>Weltman</surname> <given-names>M</given-names></name><name><surname>Bugianesi</surname> <given-names>E</given-names></name><name><surname>Spengler</surname> <given-names>U</given-names></name><name><surname>Shaker</surname> <given-names>O</given-names></name><name><surname>Fischer</surname> <given-names>J</given-names></name><name><surname>Mollison</surname> <given-names>L</given-names></name><name><surname>Cheng</surname> <given-names>W</given-names></name><name><surname>Powell</surname> <given-names>E</given-names></name><name><surname>Nattermann</surname> <given-names>J</given-names></name><name><surname>Riordan</surname> <given-names>S</given-names></name><name><surname>McLeod</surname> <given-names>D</given-names></name><name><surname>Armstrong</surname> <given-names>NJ</given-names></name><name><surname>Douglas</surname> <given-names>MW</given-names></name><name><surname>Liddle</surname> <given-names>C</given-names></name><name><surname>Booth</surname> <given-names>DR</given-names></name><name><surname>George</surname> <given-names>J</given-names></name><name><surname>Ahlenstiel</surname> <given-names>G</given-names></name><collab>International Hepatitis C Genetics Consortium (IHCGC)</collab></person-group><year iso-8601-date="2015">2015</year><article-title>Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease</article-title><source>Nature Communications</source><volume>6</volume><elocation-id>6422</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms7422</pub-id><pub-id pub-id-type="pmid">25740255</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kelemen</surname> <given-names>LE</given-names></name><name><surname>Lawrenson</surname> <given-names>K</given-names></name><name><surname>Tyrer</surname> <given-names>J</given-names></name><name><surname>Li</surname> <given-names>Q</given-names></name><name><surname>Lee</surname> <given-names>JM</given-names></name><name><surname>Seo</surname> <given-names>JH</given-names></name><name><surname>Phelan</surname> <given-names>CM</given-names></name><name><surname>Beesley</surname> <given-names>J</given-names></name><name><surname>Chen</surname> <given-names>X</given-names></name><name><surname>Spindler</surname> <given-names>TJ</given-names></name><name><surname>Aben</surname> <given-names>KK</given-names></name><name><surname>Anton-Culver</surname> <given-names>H</given-names></name><name><surname>Antonenkova</surname> <given-names>N</given-names></name><collab>Australian Cancer Study</collab><collab>Australian Ovarian Cancer Study Group</collab><collab>Ovarian Cancer Association Consortium</collab></person-group><year iso-8601-date="2015">2015</year><article-title>Genome-wide significant risk associations for mucinous ovarian carcinoma</article-title><source>Nature Genetics</source><volume>47</volume><fpage>888</fpage><lpage>897</lpage><pub-id pub-id-type="doi">10.1038/ng.3336</pub-id><pub-id pub-id-type="pmid">26075790</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Key</surname> <given-names>FM</given-names></name><name><surname>Peter</surname> <given-names>B</given-names></name><name><surname>Dennis</surname> <given-names>MY</given-names></name><name><surname>Huerta-Sánchez</surname> <given-names>E</given-names></name><name><surname>Tang</surname> <given-names>W</given-names></name><name><surname>Prokunina-Olsson</surname> <given-names>L</given-names></name><name><surname>Nielsen</surname> <given-names>R</given-names></name><name><surname>Andrés</surname> <given-names>AM</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Selection on a variant associated with improved viral clearance drives local, adaptive pseudogenization of interferon lambda 4 (<italic>IFNL4</italic>)</article-title><source>PLOS Genetics</source><volume>10</volume><elocation-id>e1004681</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1004681</pub-id><pub-id pub-id-type="pmid">25329461</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kotenko</surname> <given-names>SV</given-names></name><name><surname>Gallagher</surname> <given-names>G</given-names></name><name><surname>Baurin</surname> <given-names>VV</given-names></name><name><surname>Lewis-Antes</surname> <given-names>A</given-names></name><name><surname>Shen</surname> <given-names>M</given-names></name><name><surname>Shah</surname> <given-names>NK</given-names></name><name><surname>Langer</surname> <given-names>JA</given-names></name><name><surname>Sheikh</surname> <given-names>F</given-names></name><name><surname>Dickensheets</surname> <given-names>H</given-names></name><name><surname>Donnelly</surname> <given-names>RP</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>IFN-λs mediate antiviral protection through a distinct class II cytokine receptor complex</article-title><source>Nature Immunology</source><volume>4</volume><fpage>69</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1038/ni875</pub-id><pub-id pub-id-type="pmid">12483210</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minas</surname> <given-names>TZ</given-names></name><name><surname>Tang</surname> <given-names>W</given-names></name><name><surname>Smith</surname> <given-names>CJ</given-names></name><name><surname>Onabajo</surname> <given-names>OO</given-names></name><name><surname>Obajemu</surname> <given-names>A</given-names></name><name><surname>Dorsey</surname> <given-names>TH</given-names></name><name><surname>Jordan</surname> <given-names>SV</given-names></name><name><surname>Obadi</surname> <given-names>OM</given-names></name><name><surname>Ryan</surname> <given-names>BM</given-names></name><name><surname>Prokunina-Olsson</surname> <given-names>L</given-names></name><name><surname>Loffredo</surname> <given-names>CA</given-names></name><name><surname>Ambs</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title><italic>IFNL4</italic>-ΔG is associated with prostate cancer among men at increased risk of sexually transmitted infections</article-title><source>Communications Biology</source><volume>1</volume><fpage>191</fpage><pub-id pub-id-type="doi">10.1038/s42003-018-0193-5</pub-id><pub-id pub-id-type="pmid">30456312</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prokunina-Olsson</surname> <given-names>L</given-names></name><name><surname>Muchmore</surname> <given-names>B</given-names></name><name><surname>Tang</surname> <given-names>W</given-names></name><name><surname>Pfeiffer</surname> <given-names>RM</given-names></name><name><surname>Park</surname> <given-names>H</given-names></name><name><surname>Dickensheets</surname> <given-names>H</given-names></name><name><surname>Hergott</surname> <given-names>D</given-names></name><name><surname>Porter-Gill</surname> <given-names>P</given-names></name><name><surname>Mumy</surname> <given-names>A</given-names></name><name><surname>Kohaar</surname> <given-names>I</given-names></name><name><surname>Chen</surname> <given-names>S</given-names></name><name><surname>Brand</surname> <given-names>N</given-names></name><name><surname>Tarway</surname> <given-names>M</given-names></name><name><surname>Liu</surname> <given-names>L</given-names></name><name><surname>Sheikh</surname> <given-names>F</given-names></name><name><surname>Astemborski</surname> <given-names>J</given-names></name><name><surname>Bonkovsky</surname> <given-names>HL</given-names></name><name><surname>Edlin</surname> <given-names>BR</given-names></name><name><surname>Howell</surname> <given-names>CD</given-names></name><name><surname>Morgan</surname> <given-names>TR</given-names></name><name><surname>Thomas</surname> <given-names>DL</given-names></name><name><surname>Rehermann</surname> <given-names>B</given-names></name><name><surname>Donnelly</surname> <given-names>RP</given-names></name><name><surname>O'Brien</surname> <given-names>TR</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus</article-title><source>Nature Genetics</source><volume>45</volume><fpage>164</fpage><lpage>171</lpage><pub-id pub-id-type="doi">10.1038/ng.2521</pub-id><pub-id pub-id-type="pmid">23291588</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheppard</surname> <given-names>P</given-names></name><name><surname>Kindsvogel</surname> <given-names>W</given-names></name><name><surname>Xu</surname> <given-names>W</given-names></name><name><surname>Henderson</surname> <given-names>K</given-names></name><name><surname>Schlutsmeyer</surname> <given-names>S</given-names></name><name><surname>Whitmore</surname> <given-names>TE</given-names></name><name><surname>Kuestner</surname> <given-names>R</given-names></name><name><surname>Garrigues</surname> <given-names>U</given-names></name><name><surname>Birks</surname> <given-names>C</given-names></name><name><surname>Roraback</surname> <given-names>J</given-names></name><name><surname>Ostrander</surname> <given-names>C</given-names></name><name><surname>Dong</surname> <given-names>D</given-names></name><name><surname>Shin</surname> <given-names>J</given-names></name><name><surname>Presnell</surname> <given-names>S</given-names></name><name><surname>Fox</surname> <given-names>B</given-names></name><name><surname>Haldeman</surname> <given-names>B</given-names></name><name><surname>Cooper</surname> <given-names>E</given-names></name><name><surname>Taft</surname> <given-names>D</given-names></name><name><surname>Gilbert</surname> <given-names>T</given-names></name><name><surname>Grant</surname> <given-names>FJ</given-names></name><name><surname>Tackett</surname> <given-names>M</given-names></name><name><surname>Krivan</surname> <given-names>W</given-names></name><name><surname>McKnight</surname> <given-names>G</given-names></name><name><surname>Clegg</surname> <given-names>C</given-names></name><name><surname>Foster</surname> <given-names>D</given-names></name><name><surname>Klucher</surname> <given-names>KM</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>IL-28, IL-29 and their class II cytokine receptor IL-28R</article-title><source>Nature Immunology</source><volume>4</volume><fpage>63</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1038/ni873</pub-id><pub-id pub-id-type="pmid">12469119</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Terczyńska-Dyla</surname> <given-names>E</given-names></name><name><surname>Bibert</surname> <given-names>S</given-names></name><name><surname>Duong</surname> <given-names>FH</given-names></name><name><surname>Krol</surname> <given-names>I</given-names></name><name><surname>Jørgensen</surname> <given-names>S</given-names></name><name><surname>Collinet</surname> <given-names>E</given-names></name><name><surname>Kutalik</surname> <given-names>Z</given-names></name><name><surname>Aubert</surname> <given-names>V</given-names></name><name><surname>Cerny</surname> <given-names>A</given-names></name><name><surname>Kaiser</surname> <given-names>L</given-names></name><name><surname>Malinverni</surname> <given-names>R</given-names></name><name><surname>Mangia</surname> <given-names>A</given-names></name><name><surname>Moradpour</surname> <given-names>D</given-names></name><name><surname>Müllhaupt</surname> <given-names>B</given-names></name><name><surname>Negro</surname> <given-names>F</given-names></name><name><surname>Santoro</surname> <given-names>R</given-names></name><name><surname>Semela</surname> <given-names>D</given-names></name><name><surname>Semmo</surname> <given-names>N</given-names></name><collab>Swiss Hepatitis C Cohort Study Group</collab><name><surname>Heim</surname> <given-names>MH</given-names></name><name><surname>Bochud</surname> <given-names>PY</given-names></name><name><surname>Hartmann</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Reduced IFNλ4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes</article-title><source>Nature Communications</source><volume>5</volume><elocation-id>5699</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms6699</pub-id><pub-id pub-id-type="pmid">25534433</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname> <given-names>L</given-names></name><name><surname>Schnepf</surname> <given-names>D</given-names></name><name><surname>Becker</surname> <given-names>J</given-names></name><name><surname>Ebert</surname> <given-names>K</given-names></name><name><surname>Tanriver</surname> <given-names>Y</given-names></name><name><surname>Bernasconi</surname> <given-names>V</given-names></name><name><surname>Gad</surname> <given-names>HH</given-names></name><name><surname>Hartmann</surname> <given-names>R</given-names></name><name><surname>Lycke</surname> <given-names>N</given-names></name><name><surname>Staeheli</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Interferon-λ enhances adaptive mucosal immunity by boosting release of thymic stromal lymphopoietin</article-title><source>Nature Immunology</source><volume>20</volume><fpage>593</fpage><lpage>601</lpage><pub-id pub-id-type="doi">10.1038/s41590-019-0345-x</pub-id><pub-id pub-id-type="pmid">30886417</pub-id></element-citation></ref></ref-list></back></article>